- Home
- DIBS vs AARD Comparison
DIBS vs AARD Comparison
Compare DIBS & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DIBS | AARD |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.3M | 231.9M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DIBS | AARD |
|---|---|---|
| Price | $6.01 | $13.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.63 |
| AVG Volume (30 Days) | ★ 372.6K | 224.6K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,422,000.00 | N/A |
| Revenue This Year | $3.46 | N/A |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.49 | N/A |
| 52 Week Low | $2.30 | $4.88 |
| 52 Week High | $6.63 | $19.58 |
Technical Indicators
Market Signals| Indicator | DIBS | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 63.94 | 57.48 |
| Support Level | $5.86 | $14.27 |
| Resistance Level | $6.34 | $16.00 |
| Average True Range (ATR) | 0.35 | 1.20 |
| MACD | -0.08 | 0.17 |
| Stochastic Oscillator | 48.37 | 64.27 |
Price Performance
Historical ComparisonAbout DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The Company has a single reportable and operating segment that contains one reporting unit, which consists of the Company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.